45 related articles for article (PubMed ID: 9187131)
1. Protein palmitoylation in cancer: molecular functions and therapeutic potential.
Zhou B; Hao Q; Liang Y; Kong E
Mol Oncol; 2023 Jan; 17(1):3-26. PubMed ID: 36018061
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Sarin V; Yu K; Ferguson ID; Gugliemini O; Nix MA; Hann B; Sirota M; Wiita AP
Leukemia; 2020 Oct; 34(10):2754-2765. PubMed ID: 32123307
[TBL] [Abstract][Full Text] [Related]
3. Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines.
Weißbach S; Heredia-Guerrero SC; Barnsteiner S; Großhans L; Bodem J; Starz H; Langer C; Appenzeller S; Knop S; Steinbrunn T; Rost S; Einsele H; Bargou RC; Rosenwald A; Stühmer T; Leich E
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32079091
[TBL] [Abstract][Full Text] [Related]
4. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.
Lin YT; Way GP; Barwick BG; Mariano MC; Marcoulis M; Ferguson ID; Driessen C; Boise LH; Greene CS; Wiita AP
Blood Adv; 2019 Nov; 3(21):3214-3227. PubMed ID: 31698452
[TBL] [Abstract][Full Text] [Related]
5. IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.
Gocke CB; McMillan R; Wang Q; Begum A; Penchev VR; Ali SA; Borrello I; Huff CA; Matsui W
Mol Cancer Ther; 2016 Nov; 15(11):2733-2739. PubMed ID: 27573425
[TBL] [Abstract][Full Text] [Related]
6. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Fang B
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096
[TBL] [Abstract][Full Text] [Related]
7. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Mulligan G; Lichter DI; Di Bacco A; Blakemore SJ; Berger A; Koenig E; Bernard H; Trepicchio W; Li B; Neuwirth R; Chattopadhyay N; Bolen JB; Dorner AJ; van de Velde H; Ricci D; Jagannath S; Berenson JR; Richardson PG; Stadtmauer EA; Orlowski RZ; Lonial S; Anderson KC; Sonneveld P; San Miguel JF; Esseltine DL; Schu M
Blood; 2014 Jan; 123(5):632-9. PubMed ID: 24335104
[TBL] [Abstract][Full Text] [Related]
8. Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.
Linden MA; Kirchhof N; Carlson CS; Van Ness BG
Exp Hematol; 2012 Mar; 40(3):216-27. PubMed ID: 22120021
[TBL] [Abstract][Full Text] [Related]
9. Constitutive NF-kappaB activation confers interleukin 6 (IL6) independence and resistance to dexamethasone and Janus kinase inhibitor INCB018424 in murine plasmacytoma cells.
Yang Y; Groshong JS; Matta H; Gopalakrishnan R; Yi H; Chaudhary PM
J Biol Chem; 2011 Aug; 286(32):27988-97. PubMed ID: 21705340
[TBL] [Abstract][Full Text] [Related]
10. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.
Hiruma Y; Honjo T; Jelinek DF; Windle JJ; Shin J; Roodman GD; Kurihara N
Blood; 2009 May; 113(20):4894-902. PubMed ID: 19282458
[TBL] [Abstract][Full Text] [Related]
11. A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver.
Wangensteen KJ; Wilber A; Keng VW; He Z; Matise I; Wangensteen L; Carson CM; Chen Y; Steer CJ; McIvor RS; Largaespada DA; Wang X; Ekker SC
Hepatology; 2008 May; 47(5):1714-24. PubMed ID: 18435462
[TBL] [Abstract][Full Text] [Related]
12. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.
Li X; Pennisi A; Zhan F; Sawyer JR; Shaughnessy JD; Yaccoby S
Br J Haematol; 2007 Sep; 138(6):802-11. PubMed ID: 17760811
[TBL] [Abstract][Full Text] [Related]
13. Targeting aurora kinases as therapy in multiple myeloma.
Shi Y; Reiman T; Li W; Maxwell CA; Sen S; Pilarski L; Daniels TR; Penichet ML; Feldman R; Lichtenstein A
Blood; 2007 May; 109(9):3915-21. PubMed ID: 17213289
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.
Hoang B; Zhu L; Shi Y; Frost P; Yan H; Sharma S; Sharma S; Goodglick L; Dubinett S; Lichtenstein A
Blood; 2006 Jun; 107(11):4484-90. PubMed ID: 16497971
[TBL] [Abstract][Full Text] [Related]
15. Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse.
Carlson CM; Frandsen JL; Kirchhof N; McIvor RS; Largaespada DA
Proc Natl Acad Sci U S A; 2005 Nov; 102(47):17059-64. PubMed ID: 16286660
[TBL] [Abstract][Full Text] [Related]
16. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.
Billadeau D; Liu P; Jelinek D; Shah N; LeBien TW; Van Ness B
Cancer Res; 1997 Jun; 57(11):2268-75. PubMed ID: 9187131
[TBL] [Abstract][Full Text] [Related]
17. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.
Billadeau D; Jelinek DF; Shah N; LeBien TW; Van Ness B
Cancer Res; 1995 Aug; 55(16):3640-6. PubMed ID: 7627974
[TBL] [Abstract][Full Text] [Related]
18. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.
Rowley M; Van Ness B
Oncogene; 2002 Dec; 21(57):8769-75. PubMed ID: 12483530
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.
Rowley M; Liu P; Van Ness B
Blood; 2000 Nov; 96(9):3175-80. PubMed ID: 11050000
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
